Brind.
  1. BioCryst focuses on rare diseases like Hereditary Angioedema (HAE), and Dr. Helen Thackray led R&D efforts at the company.

ORLADEYO has seen significant revenue growth, and new treatments are being evaluated for their potential impact on the demand for HAE sufferers.

10 reports, 5 independent Updated Sep 23
No new developments lately Reached 3 outlets in its first 24 hours
Reports
10
Developments
6
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 5 independent outlets

ORLADEYO has seen significant revenue growth, and new treatments are being evaluated for their potential impact on the demand for HAE sufferers.

Who's involved

What this event is mainly about
HaeBioCryst Pharmaceuticals

How it developed

Newest first. Tap a step to see who reported it.
  1. Pending applications for market expansion in Europe and Canada for ORLADEYO.1 source
  2. BioCryst Pharmaceuticals engaged CareMed for commercial support and is advancing the oral pellet formulation of ORLADEYO.Sub-event
  3. ORLADEYO revenue grew significantly, and new HAE treatments may affect market demand.1 source
  4. BioCryst presented research on ORLADEYO at the US HAEA National Summit.
  5. BioCryst Pharmaceuticals sold its European ORLADEYO business unit.
  6. BioCryst divests ORLADEYO business to Neopharmed Gentili.

Keep exploring

Part of

BioCryst focuses on rare diseases like Hereditary Angioedema (HAE), and Dr. Helen Thackray led R&D efforts at the company. All 2 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • yahoo.com
  • manilatimes.net
  • GuruFocus.comBioCryst Pharmaceuticals Inc (BCRX) Q2 2025 Earnings Call Highlights: Record ORLADEYO Revenue ... Total Revenue: $163.4 million for Q2 2025. ORLADEYO Revenue: $156.8 million, with $140.3 million gene
  • GlobeNewswireBioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update —Q2 2025 ORLADEYO net revenue of $156.8 million (+45 percent y-o-y)— —Q2 2025 operating profit of $29.8 million (+2
  • ZacksBioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock BioCryst Pharmaceuticals BCRX is slated to report its second-quarter 2025 results on Aug. 4, before the opening bell. The Zacks Cons
  • Unknown outlet
  • Unknown outlet
  • Unknown outlet
2 more outlets ran the same wire story